Cargando…

Novel therapies for multiple myeloma

Detalles Bibliográficos
Autores principales:	Wallington-Beddoe, Craig T., Pitson, Stuart M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5611977/ https://www.ncbi.nlm.nih.gov/pubmed/28854147 http://dx.doi.org/10.18632/aging.101284

Ejemplares similares

Enhancing ER stress in myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017)

Prognostic and predictive biomarker developments in multiple myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2021)

Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies
por: Lewis, Alexander C., et al.
Publicado: (2018)

Author Correction: Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies
por: Lewis, Alexander C., et al.
Publicado: (2021)

Desmoglein‐2 expression is an independent predictor of poor prognosis patients with multiple myeloma
por: Ebert, Lisa M., et al.
Publicado: (2021)

Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017)

Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition
por: Bennett, Melissa K., et al.
Publicado: (2021)

Optimizing therapy for del(17p) multiple myeloma
por: Avet-Loiseau, Hervé, et al.
Publicado: (2017)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

Immunotherapy for Multiple Myeloma
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma
por: Krejcik, Jakub, et al.
Publicado: (2018)

New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma
por: Mesguich, Charles, et al.
Publicado: (2016)

Hyperhaploid karyotypes in multiple myeloma
por: Sawyer, Jeffrey R., et al.
Publicado: (2017)

Latest Development in Multiple Myeloma
por: Imai, Yoichi
Publicado: (2020)

Introduction to “Immunotherapies for Multiple Myeloma”
por: Offidani, Massimo, et al.
Publicado: (2020)

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

Cancer drug resistance in multiple myeloma
por: Uckun, Fatih M.
Publicado: (2022)

Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
por: Puertas, Borja, et al.
Publicado: (2022)

CAR T-cell therapy for triple-class exposed relapsed/refractory multiple myeloma
por: Cavo, Michele
Publicado: (2023)

To be or not to be: the role of CD56 in multiple myeloma
por: Cottini, Francesca, et al.
Publicado: (2023)

Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice
por: Xie, Vicki, et al.
Publicado: (2018)

Multiple mechanisms can disrupt oncogenic pathways in multiple myeloma
por: Hoang, Phuc H., et al.
Publicado: (2018)

Anti-BCMA novel therapies for multiple myeloma
por: Sammartano, Vincenzo, et al.
Publicado: (2023)

Circulating tumour DNA analysis in multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2017)

Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
por: Liberati, Anna Marina, et al.
Publicado: (2013)

Methods for reducing delays in the diagnosis of multiple myeloma
por: Koshiaris, Constantinos
Publicado: (2019)

Recent Advances on the Pathobiology and Treatment of Multiple Myeloma
por: Amodio, Nicola
Publicado: (2021)

Immunotherapy for multiple myeloma: new chances and hope
por: Xu, Jingyu, et al.
Publicado: (2023)

MRD negativity: considerations for older adults with multiple myeloma
por: Mian, Hira, et al.
Publicado: (2023)

MRD in multiple myeloma: more questions than answers?
por: Moreau, Philippe, et al.
Publicado: (2017)

The genomic features associated with high-risk multiple myeloma
por: Walker, Brian A., et al.
Publicado: (2018)

The Road to a Cure: Emerging Treatments for Multiple Myeloma
por: Caers, Jo
Publicado: (2020)

Targeted Therapy in Leukaemia, Lymphoma and Myeloma
por: Opat, Stephen Samuel
Publicado: (2022)

Proteasome inhibition: the dawn of novel therapies in multiple myeloma
por: Engelhardt, Monika, et al.
Publicado: (2022)

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma
por: Krönke, Jan, et al.
Publicado: (2017)

Imaging in multiple myeloma: Computed tomography or magnetic resonance imaging?
por: Tagliafico, Alberto Stefano
Publicado: (2021)

The hope for targeting fatty acid binding proteins in multiple myeloma
por: Fairfield, Heather, et al.
Publicado: (2023)

Yes! To Scaling Up Cervical Cancer Screening With Self-Collection: But the Cost of HPV Screening Must Be Reduced
por: Beddoe, Ann Marie
Publicado: (2021)

Proptosis with hemiplegia: Unusual presentation of multiple myeloma
por: Ghosh, K
Publicado: (2018)

RNA processing: a new player of genomic instability in multiple myeloma
por: Marchesini, Matteo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5rttdk438af8f5u1ar29f2s1qf